Teva Plans To Launch Six Biosimilars By 2027

With US Approvals In Hand, Teva And Alvotech Take Aim At Adalimumab And Ustekinumab

 
• By David Wallace
  
Pencil drawing outline of number 2027
Teva has outlined plans for six biosimilar launches by 2027 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products